Christopher G. Azzoli

Author

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Azzoli C, C G Azzoli, C. Azzoli, C. G. Azzoli, C.G. Azzoli, Champion, Victoria L., Christopher Azzoli, Christopher G Azzoli, Christopher G. Azzoli, Christopher. G. Azzoli

266

Publications

14.8K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Massachusetts General Hospital Harvard University Dana-Farber Cancer Institute

About

Christopher G. Azzoli is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	47	5.4K
2	Health Sciences	12	13	2.6K
3	Public Health	2	2	104
4	Natural Sciences	1	1	180
5	Nursing	1	1	70

Christopher G. Azzoli

Publications

10.7K

Citations

H-Index

Page 1

	Year	Citations
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, Clinical Cancer Research	2016	1.2K
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer Christopher G. Azzoli, Sherman Baker, Sarah Temin, Journal of Clinical Oncology Tumor MicroenvironmentMolecular MarkersMedicineCancer ManagementClinical Trials	2009	912
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Gregory A. Masters, Sarah Temin, Christopher G. Azzoli, Journal of Clinical Oncology Low Pd-l1 ExpressionCancer TherapeuticsPd-l1 ExpressionMedicineCancer Management	2015	847
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer Vincent A. Miller, Mark G. Kris, Neelam Shah, Journal of Clinical Oncology	2004	744
Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline Katherine M.W. Pisters, William K. Evans, Christopher G. Azzoli, Journal of Clinical Oncology	2007	361
Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors Helena A. Yu, Camelia S. Sima, James Huang, Journal of Thoracic Oncology Local TherapyOncologyAcquired ResistanceMedicinePathology	2013	337
A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors Gabriel Sica, Akihiko Yoshizawa, Camelia S. Sima, The American Journal of Surgical Pathology Grading SystemMedicineCancer RecurrenceHistopathologyPathology	2010	329
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer Christopher G. Azzoli, Sarah Temin, Timothy Aliff, Journal of Clinical Oncology	2011	287
Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma Jenifer L. Marks, Stephen Broderick, Qin Zhou, Journal of Thoracic Oncology Kras MutationsSurgical OncologyMedicinePathologyCancer Genomics	2008	272
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer Nathan A. Pennell, Joel W. Neal, Jamie E. Chaft, Journal of Clinical Oncology	2018	208

Page 1